Rate of Uninsured Cancer Patients Dropped in Medicaid Expansion States

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video examines changes in insurance status after implementation of the Affordable Care Act among cancer patients who received radiation therapy.

In this video, Fumiko Chino, MD, of Duke University Medical Center in Durham, North Carolina, discusses a study that examined changes in insurance status among cancer patients who received radiation therapy after implementation of the Affordable Care Act, both in States that expanded Medicaid and in those that did not.

Chino presented the results of the study (abstract LBA-15) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Recent Videos
Those with breast cancer who have undergone implant-based reconstruction following mastectomy have similar outcomes with hypofractionated vs conventionally fractionated radiotherapy.
PSMA-targeting PET ligand 18F-rhPSMA-7.3 yielded high detection rates for patients with recurrent prostate cancer regardless of factors such as PSA levels, PSA doubling time, or Gleason scores, according to Benjamin H. Lowenritt, MD, FACS.
Pooling data with other radiation trials, looking more closely at central non-small cell lung cancer, and exploring secondary outcomes represent the next steps in terms of analyzing stereotactic body radiation (SBRT) vs conventional hypofractionated radiotherapy (CRT), according to Anand Swaminath, MD.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Anand Swaminath, MD, reviews the design of the phase 3 LUSTRE trial comparing a 3-week conventional radiotherapy regimen with stereotactic body radiotherapy among patients with stage I medically inoperable non-small cell lung cancer.
Future focuses following the phase 3 SPOTLIGHT trial will include identifying sites of recurrence and different intensity levels for 18F-rhPSMA-7.3 in suspected recurrent prostate cancer, according to Benjamin H. Lowenritt, MD, FACS.
Stereotactic body radiation therapy yielded numerical improvements in terms of local control compared with conventional hypofractionated radiotherapy among patients with stage I medically inoperable non-small cell lung cancer, according to findings from the phase 3 LUSTRE trial.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
The goal of the analysis of the phase 3 SPOTLIGHT trial was to evaluate how clinical factors impact 18F-rhPSMA-7.3 detection rates in a population of patients with suspected recurrent prostate cancer, according to Benjamin H. Lowenritt, MD, FACS.
Data from the phase 3 LUSTRE trial indicated that stereotactic body radiotherapy is a safe and effective alternative to conventional radiation for use in patients with stage I medically-inoperable non-small lung cancer, according to an expert from Juravinski Cancer Centre in Canada.
Related Content
Findings suggest that harnessing the tumoral node microenvironment may improve the ability to predict extracapsular nodal extensions in patients with oropharyngeal carcinoma.

AI-Based Model May Improve Prediction of ECE in Oropharyngeal Cancer

Russ Conroy
March 5th 2024
Article

Findings suggest that harnessing the tumoral node microenvironment may improve the ability to predict extracapsular nodal extensions in patients with oropharyngeal carcinoma.

Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer | Image Credit: © freshidea - stock.adobe.com.

Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer

Gina Mauro
March 5th 2024
Article

Patients with factors such as lymphovascular space invasion or positive glossectomy specimen margins may be considered for adjuvant radiotherapy to optimize disease control of tongue squamous cell carcinoma.

A prospective phase 2 trial evaluated the use of de-escalation therapy for patients with p16-positive squamous cell carcinoma.

SAVER Model Shows De-Escalation Benefit in p16-Positive Oropharynx SCC

Ariana Pelosci
March 4th 2024
Article

A prospective phase 2 trial evaluated the use of de-escalation therapy for patients with p16-positive squamous cell carcinoma.

The role of multimodal approaches such as FDG-PET imaging may require further investigation in patients with human papillomavirus–positive oropharyngeal cancer, according to Samuel Regan, MD.

Chemoradiotherapy De-escalation Appears Feasible in HPV+ Oropharynx Cancer

Russ Conroy
March 4th 2024
Article

The role of multimodal approaches such as FDG-PET imaging may require further investigation in patients with human papillomavirus–positive oropharyngeal cancer, according to Samuel Regan, MD.

Radiation Therapy Plus Chemo Yielded Increased Efficacy in HPV+ Oropharynx Cancer

Radiation Therapy Plus Chemo Yielded Increased Efficacy in HPV+ Oropharynx Cancer

Gina Mauro
March 4th 2024
Article

The use of postoperative adjuvant radiation therapy led to less weight loss in patients with HPV-positive oropharynx cancer, according to Wade L. Thorstad, MD.

Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.

Pembrolizumab/Lenvatinib Combo Shows Mixed Results in Recurrent/Metastatic HNSCC

Russ Conroy
March 1st 2024
Article

Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.